Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2012

Open Access 01-10-2012 | Research article

Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritis

Authors: Marina G Kazantseva, John Highton, Lisa K Stamp, Paul A Hessian

Published in: Arthritis Research & Therapy | Issue 5/2012

Login to get access

Abstract

Introduction

Smoking increases the risk of developing rheumatoid arthritis (RA) and affects the severity of established RA. Smoking can impact on Th17 lymphocyte differentiation and function through activation of the aryl hydrocarbon receptor (AHR), a process with implications for the pathogenic mechanisms in RA that involve the cytokine, interleukin (IL)-17A. The objective of this study was to establish any effect of smoking on the inflammatory tissue lesions of rheumatoid arthritis via the AHR and IL-17A.

Methods

Twenty synovial and eighteen subcutaneous nodule tissue samples from 31 patients with RA were studied. Patient smoking status at the time of tissue collection was established. Expression of AHR, CYP1A1, AHRR, IL6, IL17A, IL17F, IL22, IL23, IL23R, IFNG, TBX21, IDO1 and FOXP3 genes were assessed in tissues and cultured cells using real-time PCR. Two-colour immunofluorescence was used to co-localise AHR and CYP1A1 protein in synovial tissues. The response of monocytes and monocyte-derived dendritic cells (mo-DCs) to the AHR agonist, benzo(a)pyrene (BaP) was compared in vitro.

Results

AHR gene expression was demonstrated in rheumatoid synovial tissues and nodules with significantly greater expression in synovia. Expression was not influenced by smoking in either tissue. Evidence of AHR activation, indicated by CYP1A1 and AHRR gene expression, was found only in synovia from patients who smoked. However, IL17A gene expression was lower in synovia from smokers. TBX21 and FOXP3 expression was not affected by smoking. Within the synovial tissues of smokers the principal cell type with evidence of AHR activation was a subset of synovial DCs. This observation was consistent with the sensitivity of human mo-DCs to BaP stimulation demonstrated in vitro. Exposure to BaP affected mo-DC function as demonstrated by decreased IL6 expression induced by PolyI:C, without affecting indoleamine 2,3 dioxygenase (IDO)1 expression.

Conclusion

Our findings show that one effect of smoking on inflamed rheumatoid synovial tissue involves activation of the AHR pathway. A subset of synovial DCs is important in the response to cigarette smoke. The potential for smoking to affect DC behaviour in joint tissues has relevance to both early and late phases of RA pathogenesis and warrants further investigation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Masdottir B, Jónsson T, Manfredsdottir V, Víkingsson A, Brekkan A, Valdimarsson H: Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatol. 2000, 39: 1202-1205. 10.1093/rheumatology/39.11.1202.CrossRef Masdottir B, Jónsson T, Manfredsdottir V, Víkingsson A, Brekkan A, Valdimarsson H: Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatol. 2000, 39: 1202-1205. 10.1093/rheumatology/39.11.1202.CrossRef
2.
go back to reference Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M, Siqurdardittir SL, Valdmansson H, Vikingsson A: The effects of tobacco smoking and rheumatoid factor seropositivity on disease aticity and joint damage in early rheumatoid arthritis. Rheumatol. 2006, 45: 734-740. 10.1093/rheumatology/kei240.CrossRef Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M, Siqurdardittir SL, Valdmansson H, Vikingsson A: The effects of tobacco smoking and rheumatoid factor seropositivity on disease aticity and joint damage in early rheumatoid arthritis. Rheumatol. 2006, 45: 734-740. 10.1093/rheumatology/kei240.CrossRef
3.
go back to reference Westhoff G, Rau R, Zink A: Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatol. 2008, 47: 849-854. 10.1093/rheumatology/ken057.CrossRef Westhoff G, Rau R, Zink A: Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatol. 2008, 47: 849-854. 10.1093/rheumatology/ken057.CrossRef
4.
go back to reference Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register: Predictors of response to anti-TNF alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatol. 2006, 45: 1558-1565. 10.1093/rheumatology/kel149.CrossRef Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register: Predictors of response to anti-TNF alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatol. 2006, 45: 1558-1565. 10.1093/rheumatology/kel149.CrossRef
5.
go back to reference Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM: Anti-TNF alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. Journal of Clinical Rheumatology. 2010, 16: 15-18. 10.1097/RHU.0b013e3181ca4a2a.CrossRefPubMed Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM: Anti-TNF alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. Journal of Clinical Rheumatology. 2010, 16: 15-18. 10.1097/RHU.0b013e3181ca4a2a.CrossRefPubMed
6.
go back to reference van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, Huizinga TW, van der Helm-van Mil AH: Prevalence of and predictive factors for sustained desease-modifying anti-rheumatic drug free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009, 60: 2262-2271. 10.1002/art.24661.CrossRefPubMed van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, Huizinga TW, van der Helm-van Mil AH: Prevalence of and predictive factors for sustained desease-modifying anti-rheumatic drug free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009, 60: 2262-2271. 10.1002/art.24661.CrossRefPubMed
7.
go back to reference MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ: Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000, 43: 30-37. 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B.CrossRefPubMed MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ: Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000, 43: 30-37. 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B.CrossRefPubMed
8.
go back to reference Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet. 2010, 376: 1094-1108. 10.1016/S0140-6736(10)60826-4.CrossRefPubMed Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet. 2010, 376: 1094-1108. 10.1016/S0140-6736(10)60826-4.CrossRefPubMed
9.
go back to reference Moreno I, Valenzuela A, Garcia A, Yelamos J, Sanchez B, Hernanz W: Association of the shared epitope with radiological severity of rheumatoid arthritis. J Rheumatol. 1996, 23: 6-9.PubMed Moreno I, Valenzuela A, Garcia A, Yelamos J, Sanchez B, Hernanz W: Association of the shared epitope with radiological severity of rheumatoid arthritis. J Rheumatol. 1996, 23: 6-9.PubMed
10.
go back to reference Valenzuela A, Gonzalez-Escribano MF, Rodriguez R, Moreno I, Garcia A, Nunez-Roldan A: Association of HLA shared epitope with joint damage progression in rheumatoid arthritis. Hum Immunol. 1999, 60: 250-254. 10.1016/S0198-8859(98)00110-4.CrossRefPubMed Valenzuela A, Gonzalez-Escribano MF, Rodriguez R, Moreno I, Garcia A, Nunez-Roldan A: Association of HLA shared epitope with joint damage progression in rheumatoid arthritis. Hum Immunol. 1999, 60: 250-254. 10.1016/S0198-8859(98)00110-4.CrossRefPubMed
11.
go back to reference van der Helm-van Mil AH, Toes RE, Huizinga TW: Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 1694-1696. 10.1136/ard.2009.123828.CrossRefPubMed van der Helm-van Mil AH, Toes RE, Huizinga TW: Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 1694-1696. 10.1136/ard.2009.123828.CrossRefPubMed
12.
go back to reference Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekeran A, Davies LR, Li W, Tan Ak, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK: TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med. 2007, 357: 1199-1209. 10.1056/NEJMoa073491.PubMedCentralCrossRefPubMed Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekeran A, Davies LR, Li W, Tan Ak, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK: TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med. 2007, 357: 1199-1209. 10.1056/NEJMoa073491.PubMedCentralCrossRefPubMed
13.
go back to reference Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L, Rioux JD: Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005, 77: 1044-1060. 10.1086/498651.PubMedCentralCrossRefPubMed Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L, Rioux JD: Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005, 77: 1044-1060. 10.1086/498651.PubMedCentralCrossRefPubMed
14.
go back to reference Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A: Smoking and risk of rheumatoid arthritis. J Rheumatol. 1993, 20: 1830-1835.PubMed Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A: Smoking and risk of rheumatoid arthritis. J Rheumatol. 1993, 20: 1830-1835.PubMed
15.
go back to reference Finckh A, Dehler S, Costenbader KH, Gabay C: Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 1066-1071. 10.1136/ard.2006.065060.PubMedCentralCrossRefPubMed Finckh A, Dehler S, Costenbader KH, Gabay C: Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 1066-1071. 10.1136/ard.2006.065060.PubMedCentralCrossRefPubMed
16.
go back to reference Harrison BJ, Silman AJ, Wiles NJ, Scott DG, Symmons DP: The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum. 2001, 44: 323-330. 10.1002/1529-0131(200102)44:2<323::AID-ANR49>3.0.CO;2-C.CrossRefPubMed Harrison BJ, Silman AJ, Wiles NJ, Scott DG, Symmons DP: The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum. 2001, 44: 323-330. 10.1002/1529-0131(200102)44:2<323::AID-ANR49>3.0.CO;2-C.CrossRefPubMed
17.
go back to reference Masdottir B, Jonsson T, Manfredsdottir V, Vikingsson A, Brekkan A, Valdimarsson H: Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatol. 2000, 39: 1202-1205. 10.1093/rheumatology/39.11.1202.CrossRef Masdottir B, Jonsson T, Manfredsdottir V, Vikingsson A, Brekkan A, Valdimarsson H: Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatol. 2000, 39: 1202-1205. 10.1093/rheumatology/39.11.1202.CrossRef
18.
go back to reference Westhoff G, Rau R, Zink A: Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatol. 2008, 47: 849-854. 10.1093/rheumatology/ken057.CrossRef Westhoff G, Rau R, Zink A: Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatol. 2008, 47: 849-854. 10.1093/rheumatology/ken057.CrossRef
19.
go back to reference Kitamura M, Kasai A: Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett. 2007, 252: 184-194. 10.1016/j.canlet.2006.11.015.CrossRefPubMed Kitamura M, Kasai A: Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett. 2007, 252: 184-194. 10.1016/j.canlet.2006.11.015.CrossRefPubMed
20.
go back to reference Makrygiannakis D, Hermansson M, Ulfgren A-K, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskpg L, Catrina AI: Smoking increases peptigylarginine deiminase 2 enzyme expression in human lungs and increases cirullination in BAL cells. Ann Rheum Dis. 2008, 67: 1488-1492. 10.1136/ard.2007.075192.CrossRefPubMed Makrygiannakis D, Hermansson M, Ulfgren A-K, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskpg L, Catrina AI: Smoking increases peptigylarginine deiminase 2 enzyme expression in human lungs and increases cirullination in BAL cells. Ann Rheum Dis. 2008, 67: 1488-1492. 10.1136/ard.2007.075192.CrossRefPubMed
21.
go back to reference Mahdi H, Fisher BA, Kallberg H, Plant D, Malmstrom V, Ronnelid J, Charles P, Ding B, Alfredsson L, Padyukov L, Symmons DP, Venables PJ, Klareskog L, Lundberg K: Specific interaction between geneotype, smoking and autoimmuity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009, 41: 1319-1324. 10.1038/ng.480.CrossRefPubMed Mahdi H, Fisher BA, Kallberg H, Plant D, Malmstrom V, Ronnelid J, Charles P, Ding B, Alfredsson L, Padyukov L, Symmons DP, Venables PJ, Klareskog L, Lundberg K: Specific interaction between geneotype, smoking and autoimmuity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009, 41: 1319-1324. 10.1038/ng.480.CrossRefPubMed
22.
go back to reference Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstom V, Feldmann M, Venables PJ: Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010, 233: 34-54. 10.1111/j.0105-2896.2009.00850.x.CrossRefPubMed Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstom V, Feldmann M, Venables PJ: Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010, 233: 34-54. 10.1111/j.0105-2896.2009.00850.x.CrossRefPubMed
23.
go back to reference Montes A, Dieguez-Gonzalez R, Perez-Pampin E, Calaza M, Mera-Varela A, Gomez-Reino JJ, Gonzalez A: Particular association of clinical and genetic features with autoimunity to citrullinated α-enolase in rheumatoid arthritis. Arthritis Rheum. 2011, 63: 654-661.CrossRefPubMed Montes A, Dieguez-Gonzalez R, Perez-Pampin E, Calaza M, Mera-Varela A, Gomez-Reino JJ, Gonzalez A: Particular association of clinical and genetic features with autoimunity to citrullinated α-enolase in rheumatoid arthritis. Arthritis Rheum. 2011, 63: 654-661.CrossRefPubMed
24.
go back to reference von Delwig A, Locke J, Robinson JH, Ng WF: Response of Th17 cells to citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum. 2010, 62: 143-149.CrossRefPubMed von Delwig A, Locke J, Robinson JH, Ng WF: Response of Th17 cells to citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum. 2010, 62: 143-149.CrossRefPubMed
25.
go back to reference Klareskog L, Ronnelid J, Lundberg K, Papyukov L, Alfredsson L: Immunity to citrullinated proteins in rheumatoid arthritis. Ann Rev Immunol. 2008, 26: 651-675. 10.1146/annurev.immunol.26.021607.090244.CrossRef Klareskog L, Ronnelid J, Lundberg K, Papyukov L, Alfredsson L: Immunity to citrullinated proteins in rheumatoid arthritis. Ann Rev Immunol. 2008, 26: 651-675. 10.1146/annurev.immunol.26.021607.090244.CrossRef
26.
go back to reference Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B: The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008, 453: 106-109. 10.1038/nature06881.CrossRefPubMed Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B: The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008, 453: 106-109. 10.1038/nature06881.CrossRefPubMed
27.
go back to reference Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U: Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther. 2009, 11: R113-10.1186/ar2772.PubMedCentralCrossRefPubMed Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U: Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther. 2009, 11: R113-10.1186/ar2772.PubMedCentralCrossRefPubMed
28.
go back to reference Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP: Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010, 12: R29-10.1186/ar2936.PubMedCentralCrossRefPubMed Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP: Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010, 12: R29-10.1186/ar2936.PubMedCentralCrossRefPubMed
29.
go back to reference Lubberts E: IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?. Cytokine. 2008, 41: 84-91. 10.1016/j.cyto.2007.09.014.CrossRefPubMed Lubberts E: IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?. Cytokine. 2008, 41: 84-91. 10.1016/j.cyto.2007.09.014.CrossRefPubMed
30.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed
31.
go back to reference Stamp LK, Easson A, Pettersson L, Highton J, Hessian PA: Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J Rheumatol. 2009, 36: 2403-2408. 10.3899/jrheum.081304.CrossRefPubMed Stamp LK, Easson A, Pettersson L, Highton J, Hessian PA: Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J Rheumatol. 2009, 36: 2403-2408. 10.3899/jrheum.081304.CrossRefPubMed
32.
go back to reference Hock BD, Starling GC, Daniel PB, Hart DN: Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology. 1994, 83: 573-581.PubMedCentralPubMed Hock BD, Starling GC, Daniel PB, Hart DN: Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology. 1994, 83: 573-581.PubMedCentralPubMed
33.
go back to reference Coventry BJ, Lee PL, Gibbs D, Hart DN: Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer. 2002, 86: 546-551. 10.1038/sj.bjc.6600132.PubMedCentralCrossRefPubMed Coventry BJ, Lee PL, Gibbs D, Hart DN: Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer. 2002, 86: 546-551. 10.1038/sj.bjc.6600132.PubMedCentralCrossRefPubMed
34.
go back to reference Hock BD, Fearnley DB, Boyce A, McLellan AD, Sorg RV, Summers KL, Hart DN: Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens. 1999, 53: 320-334. 10.1034/j.1399-0039.1999.530402.x.CrossRefPubMed Hock BD, Fearnley DB, Boyce A, McLellan AD, Sorg RV, Summers KL, Hart DN: Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens. 1999, 53: 320-334. 10.1034/j.1399-0039.1999.530402.x.CrossRefPubMed
35.
go back to reference Brauze D, Widerak M, Cwykiel J, Szyfter K, Baer-Dubowska W: The effect of aryl hydrocarbon receptor ligands on the expression of AhR, AhRR, ARNT, Hif1alpha, CYP1A1 and NQO1 genes in rat liver. Toxicol Lett. 2006, 167: 212-220. 10.1016/j.toxlet.2006.09.010.CrossRefPubMed Brauze D, Widerak M, Cwykiel J, Szyfter K, Baer-Dubowska W: The effect of aryl hydrocarbon receptor ligands on the expression of AhR, AhRR, ARNT, Hif1alpha, CYP1A1 and NQO1 genes in rat liver. Toxicol Lett. 2006, 167: 212-220. 10.1016/j.toxlet.2006.09.010.CrossRefPubMed
36.
go back to reference Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006, 54: 1122-1131. 10.1002/art.21749.CrossRefPubMed Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006, 54: 1122-1131. 10.1002/art.21749.CrossRefPubMed
37.
go back to reference Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, Toes RE, Hulzinga TW, Klareskog L, Alfredsson L: Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007, 80: 867-875. 10.1086/516736.PubMedCentralCrossRefPubMed Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, Toes RE, Hulzinga TW, Klareskog L, Alfredsson L: Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007, 80: 867-875. 10.1086/516736.PubMedCentralCrossRefPubMed
38.
go back to reference Klareskog L, Gregersen PK, Huizinga TW: Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis. 2010, 69: 2062-2066. 10.1136/ard.2010.142109.CrossRefPubMed Klareskog L, Gregersen PK, Huizinga TW: Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis. 2010, 69: 2062-2066. 10.1136/ard.2010.142109.CrossRefPubMed
39.
go back to reference Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 383-391.PubMed Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 383-391.PubMed
40.
go back to reference Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, Askling J, Alfredsson L, Klareskog L: Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011, 63: 26-36. 10.1002/art.27758.CrossRefPubMed Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, Askling J, Alfredsson L, Klareskog L: Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011, 63: 26-36. 10.1002/art.27758.CrossRefPubMed
41.
go back to reference Nguyen LP, Bradfield CA: The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 2008, 21: 102-116. 10.1021/tx7001965.PubMedCentralCrossRefPubMed Nguyen LP, Bradfield CA: The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 2008, 21: 102-116. 10.1021/tx7001965.PubMedCentralCrossRefPubMed
43.
go back to reference Bankoti J, Rase B, Simones T, Shepherd DM: Functional and phenotypic effects of AhR activation in inflammatory dendritic cells. Toxicol Appl Pharmacol. 2010, 246: 18-28. 10.1016/j.taap.2010.03.013.PubMedCentralCrossRefPubMed Bankoti J, Rase B, Simones T, Shepherd DM: Functional and phenotypic effects of AhR activation in inflammatory dendritic cells. Toxicol Appl Pharmacol. 2010, 246: 18-28. 10.1016/j.taap.2010.03.013.PubMedCentralCrossRefPubMed
44.
go back to reference Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T: Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA. 2010, 107: 19961-19966. 10.1073/pnas.1014465107.PubMedCentralCrossRefPubMed Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T: Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA. 2010, 107: 19961-19966. 10.1073/pnas.1014465107.PubMedCentralCrossRefPubMed
45.
go back to reference Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA: An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010, 185: 3190-3198. 10.4049/jimmunol.0903670.PubMedCentralCrossRefPubMed Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA: An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010, 185: 3190-3198. 10.4049/jimmunol.0903670.PubMedCentralCrossRefPubMed
46.
go back to reference Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wihelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, Stockinger B: Fate mapping of IL-17 producing T cells in inflammatory responses. Nat Immunol. 2011, 12: 255-263. 10.1038/ni.1993.PubMedCentralCrossRefPubMed Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wihelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, Stockinger B: Fate mapping of IL-17 producing T cells in inflammatory responses. Nat Immunol. 2011, 12: 255-263. 10.1038/ni.1993.PubMedCentralCrossRefPubMed
Metadata
Title
Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritis
Authors
Marina G Kazantseva
John Highton
Lisa K Stamp
Paul A Hessian
Publication date
01-10-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4046

Other articles of this Issue 5/2012

Arthritis Research & Therapy 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.